<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371446">
  <stage>Registered</stage>
  <submitdate>5/09/2016</submitdate>
  <approvaldate>26/09/2016</approvaldate>
  <actrnumber>ACTRN12616001344482</actrnumber>
  <trial_identification>
    <studytitle>Comparing the efficacy of prulifloxacin against cefixime as a preventive treatment before transrectal ultrasound guided prostate biopsy.</studytitle>
    <scientifictitle>Evaluating the efficacy of prulifloxacin against cefixime administration before a transrectal prostate biopsy, in order to avoid severe urinary sepsis after the performance. </scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate cancer suspicious </healthcondition>
    <healthcondition>Urinary tract infection</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients eligible for prostate biopsy will receive either oral tablet prulifloxacin 600mg once daily for three days (Group 1) or oral tablet cefixime 400mg (Group 2) once daily for three days, as prevention treatment before biopsy. Monitoring will be based on high fever followed with lower urinary tract symptoms up to 3 days after the performance,
The adherence to the treatment will be checked, as patinets are asked to recieve each drug some hours before biopsy, inside the urology department.</interventions>
    <comparator>Cefixime/ Prulifloxacin (control treatment)</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>High fever with lower urinary tract symptoms 

These will be chcked by self thermometry by the patient, as well as medical history is required.</outcome>
      <timepoint>1 day after prostate biopsy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Severe sepsis
Evaluation will be performed with:

Blood and urine examintaions and cultures.
Blood gas, respiratory frequence, blood pressure.

</outcome>
      <timepoint>3 days after prostate biopsy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients eligible for prostate biopsy </inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prulifloxacin or cefixime allergy

Kidney failure, 

Known resistance to prulifloxacin or cefixime</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/11/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>15/10/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaly</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Thessaly</primarysponsorname>
    <primarysponsoraddress>Mezourlo 41100 Larissa

</primarysponsoraddress>
    <primarysponsorcountry>Greece</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Thessaly</fundingname>
      <fundingaddress>Mezourlo, 41100, Larissa

</fundingaddress>
      <fundingcountry>Greece</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients eligible for prostate biopsy, either after a high PSA or a DRE finding, will receive a dose of prulifloxacin 600mg (Group 1) or cefixime 400mg (Group 2) before the performance, in order to test if lower urinary tract infection or sepsis can be prevented. They will be evaluated for urinary infection in the following 3 days, based on fever and lower urinary tract symptoms. The results will be statistically studied so as to prove any difference between the two Groups.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Scientific Committee University Hospital of Larisa</ethicname>
      <ethicaddress>Viopolis Mezourlo
41100
Larisa</ethicaddress>
      <ethicapprovaldate>1/08/2016</ethicapprovaldate>
      <hrec>30025</hrec>
      <ethicsubmitdate>25/07/2016</ethicsubmitdate>
      <ethiccountry>Greece</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Vasileios Tzortzis</name>
      <address>Urology Assistant Profesor, Urology Department of University of Thessaly
Viopolis Mezourlo
41100
Larisa</address>
      <phone>+302413502811</phone>
      <fax />
      <email>tzorvas@otenet.gr</email>
      <country>Greece</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Samarinas</name>
      <address>Urologist, Urology Department of University of Thessaly
Viopolis Mezourlo
41100
Larisa</address>
      <phone>+306946006798</phone>
      <fax />
      <email>mikesamih@hotmail.com</email>
      <country>Greece</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Samarinas</name>
      <address>Urology Resident, Urology Department of University of Thessaly
Viopolis Mezourlo
41100
Larisa</address>
      <phone>+306946006798</phone>
      <fax />
      <email>mikesamih@hotmail.com</email>
      <country>Greece</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Samarinas</name>
      <address>Urology Resident, Urology Department of University of Thessaly
Viopolis Mezourlo
41100
Larisa</address>
      <phone>+306946006798</phone>
      <fax />
      <email>mikesamih@hotmail.com</email>
      <country>Greece</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>